<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Diagnosis of adrenal insufficiency in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Diagnosis of adrenal insufficiency in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Diagnosis of adrenal insufficiency in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lynnette K Nieman, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Hershel Raff, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anthony DeSantis, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            André Lacroix, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kathryn A Martin, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jean E Mulder, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 28, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical presentation of adrenal insufficiency is variable, depending on whether the onset is acute, leading to adrenal crisis, or chronic, with symptoms that are insidious and vague. The diagnosis of adrenal insufficiency depends upon a critical level of clinical suspicion. Measurements of serum cortisol within three hours after wakening (eg, 6 to 9 AM) can suggest the diagnosis of adrenal insufficiency. However, these measurements often cannot definitively establish the presence or absence of adrenal insufficiency. The
         <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">
          ACTH stimulation test
         </a>
         is the best test to diagnose or exclude adrenal insufficiency when the baseline cortisol value is indeterminate.
        </p>
        <p>
         This topic provides an overview of testing for diagnosis of adrenal insufficiency in adults. The clinical manifestations, evaluation to determine the etiology, and management of adrenal insufficiency are reviewed in detail separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/159.html" rel="external">
          "Clinical manifestations of adrenal insufficiency in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/154.html" rel="external">
          "Determining the etiology of adrenal insufficiency in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/155.html" rel="external">
          "Treatment of adrenal insufficiency in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3586938083">
         <span class="h1">
          WHOM TO TEST
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diagnostic testing should be performed in adults with signs and symptoms of adrenal insufficiency. The symptoms of adrenal insufficiency may be subtle, and the diagnosis of adrenal insufficiency depends upon a critical level of clinical suspicion. (See
         <a class="medical medical_review" href="/z/d/html/159.html" rel="external">
          "Clinical manifestations of adrenal insufficiency in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adrenal crisis
         </strong>
         – Adrenal crisis should be suspected in patients who present with peripheral vascular collapse (vasodilatory shock), whether or not the patient is known to have adrenal insufficiency  (
         <a class="graphic graphic_table graphicRef78490" href="/z/d/graphic/78490.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/159.html" rel="external">
          "Clinical manifestations of adrenal insufficiency in adults", section on 'Adrenal crisis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chronic adrenal insufficiency
         </strong>
         – Chronic adrenal insufficiency (primary or central) should be suspected in patients with a combination of fatigue, weakness, myalgias, arthralgias, anorexia, and/or weight loss  (
         <a class="graphic graphic_table graphicRef57534" href="/z/d/graphic/57534.html" rel="external">
          table 2
         </a>
         ). Hyponatremia may be present in patients with primary or central adrenal insufficiency. Hyperkalemia is only seen in primary adrenal insufficiency, as the renin-angiotensin-aldosterone system is intact in secondary adrenal insufficiency. Additionally, postural hypotension, salt craving, and hyperpigmentation may be present only in chronic primary adrenal insufficiency. (See
         <a class="medical medical_review" href="/z/d/html/159.html" rel="external">
          "Clinical manifestations of adrenal insufficiency in adults", section on 'Chronic adrenal insufficiency'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Isolated corticotropin (ACTH) deficiency
         </strong>
         – Isolated ACTH deficiency, although rare, should be considered in any adult patient who has unexplained severe hypoglycemia or hyponatremia. (See
         <a class="medical medical_review" href="/z/d/html/173.html" rel="external">
          "Causes of secondary and tertiary adrenal insufficiency in adults", section on 'Isolated ACTH deficiency'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients taking chronic glucocorticoid therapy
         </strong>
         – Administration of exogenous glucocorticoids (eg, for rheumatic diseases) can suppress the hypothalamic-pituitary-adrenal (HPA) axis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Glucocorticoid withdrawal
         </strong>
         – Abrupt cessation or reduction of therapeutic doses of glucocorticoids to subphysiologic replacement doses may cause symptoms of adrenal insufficiency. Identifying central adrenal insufficiency in this population is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7983.html" rel="external">
          "Glucocorticoid withdrawal", section on 'Identifying patients with HPA suppression'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Preoperative evaluation
         </strong>
         – Chronic glucocorticoid treatment may prevent the adrenal glands from responding appropriately during times of stress (eg, surgery). The approach to preoperative testing for HPA axis suppression should be individualized. Most patients who receive therapeutic dose of glucocorticoids do not routinely require evaluation of the HPA axis (or perioperative stress doses of glucocorticoids), provided they continue to receive their usual daily dose of glucocorticoid (or its equivalent parenteral dose). The decision to perform preoperative evaluation of the HPA axis and to give additional perioperative glucocorticoid coverage is based upon the patient's history of glucocorticoid intake and likelihood of HPA axis suppression, as well as the type and duration of surgery. This issue is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/146.html" rel="external">
          "The management of the surgical patient taking glucocorticoids", section on 'Approach based upon HPA axis suppression'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/146.html" rel="external">
          "The management of the surgical patient taking glucocorticoids", section on 'Intermediate patients'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Perioperative management of patients taking chronic glucocorticoids for the treatment of primary or central adrenal insufficiency is also reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/155.html" rel="external">
          "Treatment of adrenal insufficiency in adults", section on 'Surgery'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3435931062">
         <span class="h1">
          DIAGNOSTIC TESTING
         </span>
        </p>
        <p class="headingAnchor" id="H208773972">
         <span class="h2">
          Biochemical tests
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Basal and corticotropin (ACTH)-stimulated serum cortisol
         </strong>
         – The diagnosis of adrenal insufficiency depends on the demonstration of inappropriately low cortisol production. Total serum cortisol is the preferred measurement, except in patients with abnormalities of corticosteroid-binding globulin (CBG) or albumin (eg, patients with decreased CBG due to advanced cirrhosis or nephrotic syndrome, or those with increased CBG due to oral estrogens) [
         <a href="#rid1">
          1
         </a>
         ]. In the setting of abnormal CBG, the usual serum cortisol thresholds may lead to an incorrect diagnosis. Measurements of salivary cortisol may be useful in patients with abnormalities of CBG, although few laboratories have established ACTH-stimulated salivary cortisol thresholds. (See
         <a class="local">
          'Abnormal CBG'
         </a>
         below and
         <a class="local">
          'Basal salivary cortisol'
         </a>
         below and
         <a class="local">
          'ACTH-stimulated salivary cortisol'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although basal cortisol levels can suggest the diagnosis of adrenal insufficiency, these measurements often cannot definitively establish the presence or absence of adrenal insufficiency, particularly in the outpatient setting. Cortisol secretion is episodic [
         <a href="#rid2">
          2
         </a>
         ]. A single early morning serum cortisol value may be inconclusive [
         <a href="#rid3">
          3
         </a>
         ]. When the baseline cortisol value is inconclusive or if the clinical assessment is discordant with the cortisol findings, an
         <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">
          ACTH stimulation test
         </a>
         is needed to diagnose or exclude adrenal insufficiency. (See
         <a class="local">
          'Basal serum cortisol testing'
         </a>
         below and
         <a class="local">
          'ACTH stimulation tests'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aldosterone and renin
         </strong>
         – Some UpToDate contributors measure aldosterone and renin levels after a diagnosis of adrenal insufficiency is established to help distinguish between primary and central adrenal insufficiency. (See
         <a class="medical medical_review" href="/z/d/html/154.html" rel="external">
          "Determining the etiology of adrenal insufficiency in adults", section on 'ACTH interpretation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other UpToDate contributors measure aldosterone and renin as part of the diagnostic evaluation of suspected primary adrenal insufficiency, in part because cortisol results can be equivocal. The morning cortisol reference range is broad, and a patient can have adrenal insufficiency but maintain basal ACTH and/or cortisol secretion within the range of normal. In the early evolution of primary adrenal insufficiency in particular, a low aldosterone and elevated renin level can precede overt cortisol deficiency and elevation in ACTH [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dehydroepiandrosterone sulfate (DHEAS)
         </strong>
         – We typically measure DHEAS when initial biochemical testing with cortisol and ACTH is indeterminate. However, some UpToDate contributors measure DHEAS in all patients with suspected adrenal insufficiency. (See
         <a class="local">
          'DHEAS'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H578185374">
         <span class="h2">
          Influence of cortisol assay technique
         </span>
         <span class="headingEndMark">
          —
         </span>
         The interpretation of the cortisol result depends on the type of assay that is used to measure it [
         <a href="#rid4">
          4-10
         </a>
         ]. Available techniques include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunoassays using polyclonal antibodies
         </strong>
         – These antibodies cross-react with non-cortisol glucocorticoids, and, therefore, these older assays give a higher cortisol result than assays using more specific monoclonal antibodies or liquid chromatography-tandem mass spectrometry (LC-MS/MS).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunoassays using a more specific monoclonal antibody to cortisol
         </strong>
         – When using these more specific (less cross-reactive) assays, the morning cortisol threshold to
         <em>
         </em>
         exclude adrenal insufficiency is approximately 25 to 30 percent lower than that used with older immunoassays.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          LC-MS/MS
         </strong>
         – LC-MS/MS is a structurally based technique that does not use antibodies. It is considered to provide the most accurate measurement of cortisol. The threshold to exclude adrenal insufficiency is approximately 25 to 30 percent lower than that used with older, less specific immunoassays. LC-MS/MS is not routinely used for serum cortisol analysis.
        </p>
        <p>
        </p>
        <p>
         The importance of the type of cortisol assay employed for diagnostic testing has not been evaluated in the context of adrenal crisis (see
         <a class="local">
          'Suspected adrenal crisis'
         </a>
         below). However, in patients with suspected chronic adrenal insufficiency, the interpretation of the serum cortisol result depends on the assay used to measure it. (See
         <a class="local">
          'Suspected chronic adrenal insufficiency'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1003008432">
         <span class="h1">
          BASAL SERUM CORTISOL TESTING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Basal serum cortisol levels can be used to exclude the diagnosis of adrenal insufficiency and to select patients for additional evaluation with corticotropin (ACTH) stimulation testing [
         <a href="#rid11">
          11
         </a>
         ]. Test results must always be interpreted in conjunction with clinical assessment of the likelihood of adrenal insufficiency in an individual patient.
        </p>
        <p class="headingAnchor" id="H1619874085">
         <span class="h2">
          Suspected adrenal crisis
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with suspected adrenal crisis, we measure the serum cortisol and plasma ACTH level after inserting an intravenous (IV) line. The cortisol does not need to be measured in the early morning in the setting of suspected adrenal crisis. Therapy with IV
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         and glucocorticoid should be initiated immediately. Treatment of patients with suspected adrenal crisis should not be delayed pending results. (See
         <a class="medical medical_review" href="/z/d/html/155.html" rel="external">
          "Treatment of adrenal insufficiency in adults", section on 'Adrenal crisis'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cortisol &lt;18 mcg/dL
         </strong>
         – In hypotensive patients considered to be in adrenal crisis, a basal serum cortisol level &lt;18 mcg/dL (&lt;500 nmol/L) suggests the diagnosis of adrenal insufficiency. To confirm the diagnosis of adrenal insufficiency, ACTH stimulation testing should be performed at a later date. If supraphysiologic doses of glucocorticoids (40 to 200 mg of
         <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">
          hydrocortisone
         </a>
         daily) have not been given for more than a few days, an
         <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">
          ACTH stimulation test
         </a>
         can be performed after initiation of glucocorticoid treatment. Withhold glucocorticoids on the morning of the test and resume after the test is completed while awaiting results. (See
         <a class="local">
          'ACTH stimulation tests'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The plasma ACTH level is useful in determining the etiology of adrenal insufficiency. (See
         <a class="medical medical_review" href="/z/d/html/154.html" rel="external">
          "Determining the etiology of adrenal insufficiency in adults", section on 'Establish the level of defect'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cortisol ≥18 mcg/dL
         </strong>
         – If the basal serum cortisol level is ≥18 mcg/dL (≥500 nmol/L), adrenal insufficiency is unlikely. However, caution should be used when interpreting the cortisol results in patients with increased corticosteroid-binding globulin (CBG) levels, as may occur in pregnant individuals and those taking oral estrogens (eg, oral contraceptives, especially at a dose of 30 mcg or higher). Patients with CBG excess may have adrenal insufficiency even with apparently normal cortisol values. In the setting of CBG excess, therefore, the diagnosis of adrenal insufficiency may be missed. (See
         <a class="local">
          'Abnormal CBG'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3283294626">
         <span class="h2">
          Suspected chronic adrenal insufficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with suspected chronic adrenal insufficiency, we measure a serum cortisol level within three hours after wakening (eg, 6 to 9 AM)  (
         <a class="graphic graphic_algorithm graphicRef139990" href="/z/d/graphic/139990.html" rel="external">
          algorithm 1
         </a>
         ). When the clinical suspicion for chronic adrenal insufficiency is high, we obtain both serum cortisol and plasma ACTH levels simultaneously. If a diagnosis of adrenal insufficiency is established, the ACTH level is used to distinguish between primary and central adrenal insufficiency  (
         <a class="graphic graphic_algorithm graphicRef141555" href="/z/d/graphic/141555.html" rel="external">
          algorithm 2
         </a>
         ). If the ACTH is indeterminate, measurement of aldosterone and renin may help distinguish between the two possibilities. (See
         <a class="local">
          'Biochemical tests'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/154.html" rel="external">
          "Determining the etiology of adrenal insufficiency in adults", section on 'ACTH interpretation'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Morning
         </strong>
         <strong>
          cortisol thresholds
         </strong>
         – The interpretation of the serum cortisol result depends on the assay used to measure it. (See
         <a class="local">
          'Influence of cortisol assay technique'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When using the more specific (less cross-reactive) assays, the morning cortisol threshold to exclude chronic adrenal insufficiency is approximately 25 to 30 percent lower than the older cortisol assays (eg, approximately 13.0 to 14.0 mcg/dL instead of 18 mcg/dL [360 to 390 nmol/L instead of 500 nmol/L]) [
         <a href="#rid4">
          4,9,12
         </a>
         ]. As an example, in a study comparing results of three different cortisol immunoassays, the lowest
         <strong>
          morning
         </strong>
         serum cortisol concentration that excluded adrenal insufficiency ranged from 12.1 mcg/dL to 18.2 mcg/dL (336 nmol/L to 506 nmol/L) [
         <a href="#rid4">
          4
         </a>
         ]. A value below 2 to 3.7 mcg/dL (56 to 102 nmol/L) was consistent with adrenal insufficiency. In another study using two different cortisol assays, the morning serum cortisol threshold to exclude adrenal insufficiency ranged from &gt;12.4 to &gt;14.5 mcg/dL (340 to 400 nmol/L) [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We use the following thresholds for interpretation of early morning (6 to 9 AM or within three hours of morning waking) serum cortisol values  (
         <a class="graphic graphic_algorithm graphicRef139990" href="/z/d/graphic/139990.html" rel="external">
          algorithm 1
         </a>
         ). Clinical judgement is used in conjunction with the cortisol results to determine whether ACTH stimulation testing should be performed. As an example, if there is discordance between symptoms and early morning cortisol levels, an ACTH test should always be performed. (See
         <a class="local">
          'ACTH stimulation tests'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cortisol ≤3 mcg/dL
         </strong>
         – A low early morning serum cortisol concentration (≤3 mcg/dL [80 nmol/L]) in the absence of CBG deficiency is consistent with adrenal insufficiency [
         <a href="#rid13">
          13-15
         </a>
         ]. When multiple symptoms correlate with the low cortisol value, ACTH stimulation testing typically is not needed to confirm the diagnosis.
         <span class="utd-adt-cnt utd-adt-labi">
          (Related Lab Interpretation Monograph(s):
          <a class="narrative narrative_labi" href="/contents/low-cortisol-in-adults?topicRef=157&amp;source=see_link">
           "Low cortisol in adults"
          </a>
          .)
         </span>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         If symptoms do not correlate, perform an
         <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">
          ACTH stimulation test
         </a>
         . Normal serum cortisol responses to ACTH and insulin tolerance test (ITT) have been demonstrated for baseline serum cortisol concentration as low as approximately 1.2 to 5 mcg/dL (34 to 125 nmol/L) [
         <a href="#rid1">
          1,7,9,16-19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cortisol &gt;3 mcg/dL but &lt;18 mcg/dL
         </strong>
         – If the morning serum cortisol concentration is &gt;3 mcg/dL (&gt;80 nmol/L) but &lt;18 mcg/dL (&lt;500 nmol/L) using an older cortisol assay, perform a standard
         <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">
          ACTH stimulation test
         </a>
         . With less cross-reactive cortisol assays, the upper threshold is
         <strong>
          13 to 14 mcg/dL
         </strong>
         (360 to 390 nmol/L) instead of 18 mcg/dL (ie, perform ACTH stimulation test if cortisol is &gt;3 mcg/dL but &lt;13 to 14 mcg/dL). (See
         <a class="local">
          'ACTH stimulation tests'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cortisol ≥18 mcg/dL
         </strong>
         – An early morning serum cortisol concentration ≥18 mcg/dL (≥500 nmol/L) in the absence of CBG excess (eg, due to oral estrogen use) excludes adrenal insufficiency [
         <a href="#rid20">
          20
         </a>
         ]. When cortisol is measured using less cross-reactive assays (eg, using more specific immunoassays or liquid chromatography-tandem mass spectrometry [LC-MS/MS]), the morning cortisol threshold to exclude adrenal insufficiency is approximately 25 to 30 percent lower (eg,
         <strong>
          13 to 14 mcg/dL
         </strong>
         instead of 18 mcg/dL [360 to 390 nmol/L instead of 500 nmol/L]). (See
         <a class="local">
          'Abnormal CBG'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4197626103">
         <span class="h1">
          DHEAS
         </span>
         <span class="headingEndMark">
          —
         </span>
         We typically measure dehydroepiandrosterone sulfate (DHEAS) when biochemical testing with cortisol and corticotropin (ACTH) is indeterminate. However, some UpToDate contributors measure DHEAS in all patients with suspected adrenal insufficiency.
        </p>
        <p>
         A normal DHEAS (using an age- and sex-specific reference range) makes adrenal insufficiency unlikely. DHEAS levels are low in people with primary or central adrenal insufficiency [
         <a href="#rid21">
          21
         </a>
         ]. Although a low serum DHEAS may raise the clinical suspicion of adrenal insufficiency or support the diagnosis, it is not used as a single test to diagnose adrenal insufficiency. Patients with indeterminate cortisol levels and low (or indeterminate) serum DHEAS should undergo ACTH stimulation testing. (See
         <a class="local">
          'Standard high-dose ACTH stimulation test'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          ACTH STIMULATION TESTS
         </span>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Standard high-dose ACTH stimulation test
         </span>
         <span class="headingEndMark">
          —
         </span>
         A standard high-dose (250 mcg) corticotropin (ACTH) stimulation test should be performed to establish the diagnosis of adrenal insufficiency in patients with equivocal serum cortisol values in whom hypoadrenalism is suspected. Patients taking glucocorticoids must withhold them on the morning of the test and resume after the test is completed while awaiting results. (See
         <a class="local">
          'Suspected adrenal crisis'
         </a>
         above.)
        </p>
        <p>
         The agent used is synthetic ACTH(1-24) (cosyntropin; tetracosactin), which has the full biologic potency of native ACTH(1-39). Administration of a 250 mcg dose of ACTH(1-24) results in supraphysiologic plasma ACTH concentrations of approximately 60,000 pg/mL (1320 pmol/L) [
         <a href="#rid22">
          22,23
         </a>
         ] and thus evaluates the maximal cortisol secretory capacity. The physiologic basis of the test is that adrenocortical destruction (in primary adrenal insufficiency) or adrenocortical atrophy (due to loss of the trophic action of endogenous ACTH) will lead to a subnormal cortisol response to a pharmacologic dose of synthetic ACTH.
        </p>
        <p>
         If the loss of ACTH trophic action is recent (eg, within four to six weeks after pituitary surgery), the
         <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">
          ACTH stimulation test
         </a>
         may be falsely normal if adrenal atrophy has not occurred. Other diagnostic tests (eg, insulin-induced hypoglycemia, metyrapone-induced hypocortisolemia) may be warranted in this setting. (See
         <a class="local">
          'Recent ACTH deficiency'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/6639.html" rel="external">
          "Diagnostic testing for hypopituitarism", section on 'Corticotropin'
         </a>
         .)
        </p>
        <p>
         Generally, there are no adverse effects of the stimulation test. Allergic reactions are extraordinarily rare [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3351356262">
         <span class="h3">
          Procedure
         </span>
         <span class="headingEndMark">
          —
         </span>
         The standard high-dose (250 mcg)
         <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">
          ACTH stimulation test
         </a>
         can be performed at any time of day when using the serum cortisol response to ACTH injection to establish the diagnosis of adrenal insufficiency. The testing is performed as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obtain baseline serum cortisol.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administer cosyntropin 250 mcg (85 nmol, or 40 international units [the entire contents of the vial]) via intravenous (IV) or intramuscular (IM) injection [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obtain serum cortisol again at 30 and 60 minutes post-injection.
        </p>
        <p>
        </p>
        <p>
         If baseline ACTH, renin, and aldosterone levels are being obtained with the stimulation test (to determine the etiology of adrenal insufficiency), the test must be performed in the morning, between 6 and 9 AM, as the normal decrease in hormone levels later in the day overlaps with values observed in central adrenal insufficiency. Measurement of serum electrolytes and plasma renin activity in the basal sample can be useful because they may help to interpret measurement of basal aldosterone. In primary adrenal insufficiency, all adrenal zones are typically affected, and aldosterone will be low with an elevated renin level. In central adrenal insufficiency, the renin-angiotensin system is intact, and plasma renin and aldosterone are usually unaffected [
         <a href="#rid25">
          25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/154.html" rel="external">
          "Determining the etiology of adrenal insufficiency in adults", section on 'ACTH interpretation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3494666628">
         <span class="h3">
          Interpretation of results
         </span>
         <span class="headingEndMark">
          —
         </span>
         Only the absolute thresholds are used to exclude or diagnose adrenal insufficiency. Incremental or percent increases in cortisol should
         <strong>
          not
         </strong>
         be used to assess the response to ACTH [
         <a href="#rid26">
          26
         </a>
         ], because individuals who have a high basal serum cortisol concentration, due either to normal circadian rhythmicity or acute stress, may be nearly maximally stimulated and unable to increase cortisol secretion further. In addition, approximately 20 percent of healthy individuals with high-normal basal serum cortisol concentration have little or no rise after ACTH.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Serum cortisol
         </strong>
         – Interpretation of the
         <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">
          ACTH stimulation test
         </a>
         is based on the
         <strong>
          peak
         </strong>
         cortisol value, which typically occurs 60 minutes after administration (but may occur at 30 minutes, particularly when cosyntropin is administered intravenously)  (
         <a class="graphic graphic_algorithm graphicRef139990" href="/z/d/graphic/139990.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid27">
          27,28
         </a>
         ]. In general, the 30-minute cutoff is lower than the 60-minute value regardless of the cortisol assay method [
         <a href="#rid29">
          29,30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The ACTH-stimulated cortisol thresholds to exclude adrenal insufficiency vary with the assay used to measure cortisol  (
         <a class="graphic graphic_table graphicRef134375" href="/z/d/graphic/134375.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid8">
          8,16,31
         </a>
         ] (see
         <a class="local">
          'Influence of cortisol assay technique'
         </a>
         above). In studies evaluating the less cross-reactive cortisol assays to establish diagnostic thresholds for ACTH stimulation testing, peak cortisol levels that excluded adrenal insufficiency ranged from 14 to 18 mcg/dL (390 to 500 nmol/L) [
         <a href="#rid16">
          16,18,29,30,32
         </a>
         ]. Using a peak ACTH-stimulated cortisol threshold of 17 to 18 mcg/dL (470 to 500 nmol/L) to exclude adrenal insufficiency is unlikely to miss a diagnosis of adrenal insufficiency, but it may lead to overdiagnosis in the more specific assays.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Our approach to interpreting the
         <strong>
          peak
         </strong>
         serum cortisol value after ACTH administration is as follows  (
         <a class="graphic graphic_algorithm graphicRef139990" href="/z/d/graphic/139990.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid16">
          16,18,29,30,32
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          &lt;14 mcg/dL (390 nmol/L)
         </strong>
         – Adrenal insufficiency likely.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          ≥14 to &lt;18 mcg/dL (390 to 500 nmol/L)
         </strong>
         – The interpretation of the cortisol result depends on the type of assay that is used to measure it  (
         <a class="graphic graphic_table graphicRef134375" href="/z/d/graphic/134375.html" rel="external">
          table 3
         </a>
         ) and the clinical likelihood of adrenal insufficiency in an individual patient. If the assay type is unknown or diagnosis is uncertain, a DHEAS level may be useful. A normal DHEAS (using an age- and sex-specific reference range) makes adrenal insufficiency unlikely. (See
         <a class="local">
          'DHEAS'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          ≥18 mcg/dL (500 nmol/L)
         </strong>
         – Adrenal insufficiency generally excluded regardless of assay used to measure cortisol.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Exceptions include measurements obtained within four to six weeks of interventions (such as pituitary surgery or radiation) that may damage the hypothalamus or pituitary, or measurements obtained in patients with abnormal corticosteroid-binding globulin (CBG) levels. (See
         <a class="local">
          'Recent ACTH deficiency'
         </a>
         below and
         <a class="local">
          'Abnormal CBG'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         After cortisol deficiency is diagnosed, determine the level of the defect  (
         <a class="graphic graphic_algorithm graphicRef141555" href="/z/d/graphic/141555.html" rel="external">
          algorithm 2
         </a>
         ) and the etiology, if unknown. Determining the etiology of adrenal insufficiency is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/154.html" rel="external">
          "Determining the etiology of adrenal insufficiency in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/173.html" rel="external">
          "Causes of secondary and tertiary adrenal insufficiency in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/166.html" rel="external">
          "Causes of primary adrenal insufficiency (Addison disease)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Low-dose ACTH stimulation test not recommended
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the low-dose (1 mcg) corticotropin (ACTH) stimulation test had been proposed as a better test for central adrenal insufficiency, we do not typically use the low-dose stimulation test in clinical practice for a number of reasons:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It does not provide better diagnostic accuracy than the standard test [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There are no commercially available preparations of "low-dose" cosyntropin, and it is difficult to precisely measure diluted ACTH(1-24) for injection. A small error in dilution or injection volume or a small loss of the drug during the injection can result in a physiologically significant variability in the plasma ACTH levels achieved [
         <a href="#rid33">
          33-35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The aldosterone response is considered to be unreliable [
         <a href="#rid33">
          33,36-38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The 1 mcg low-dose test has not been validated after IM injection and may not provide valid results by this route [
         <a href="#rid39">
          39,40
         </a>
         ]. Additionally, criteria for interpretation are not available for patients whose body surface area is significantly larger or smaller than 1.73 m
         <sup>
          2
         </sup>
         .
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2589413500">
         <span class="h1">
          SPECIAL SITUATIONS WHEN STANDARD TESTING MAY BE UNRELIABLE
         </span>
        </p>
        <p>
         There are several situations when standard testing may be unreliable.
        </p>
        <p class="headingAnchor" id="H1922364340">
         <span class="h2">
          Abnormal CBG
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with abnormalities of corticosteroid-binding globulin (CBG) or albumin, such as patients taking oral estrogens (high CBG) or those with cirrhosis or nephrotic syndrome (low CBG), the usual cortisol thresholds may lead to an incorrect diagnosis [
         <a href="#rid41">
          41-43
         </a>
         ]. Serum free cortisol has been suggested as an alternative, but the assay is not widely available, and criteria for response have not been well developed [
         <a href="#rid44">
          44
         </a>
         ]. Salivary cortisol correlates well with serum free cortisol [
         <a href="#rid41">
          41
         </a>
         ]. Measurements of salivary cortisol are not affected significantly by oral contraceptives or in the presence of low CBG (eg, cirrhosis), but assay-specific cutoff points for morning and stimulated values must be used [
         <a href="#rid41">
          41,45,46
         </a>
         ]. (See
         <a class="local">
          'Basal salivary cortisol'
         </a>
         below and
         <a class="local">
          'ACTH-stimulated salivary cortisol'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/161.html" rel="external">
          "Measurement of cortisol in serum and saliva", section on 'Measurement of salivary cortisol concentration'
         </a>
         .)
        </p>
        <p>
         If the clinical suspicion for adrenal insufficiency is high and available tests to diagnose adrenal insufficiency are indeterminate due to the CBG abnormality, we generally treat with glucocorticoids until definitive biochemical testing can be performed.
        </p>
        <p class="headingAnchor" id="H3594345322">
         <span class="h3">
          High CBG
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the setting of possible high corticosteroid-binding globulin (CBG; eg, oral contraceptive use, pregnancy), it is useful to measure CBG. If normal, the usual testing can be pursued. If CBG is elevated, we measure an early morning serum cortisol. Only a frankly subnormal cortisol value (≤3 mcg/dL [83 nmol/L]) is useful to make the diagnosis of adrenal insufficiency. Values &gt;3 mcg/dL neither confirm nor exclude a diagnosis of adrenal insufficiency. If the serum cortisol is &gt;3 mcg/dL, salivary cortisol testing (if available) can be used to assess for adrenal insufficiency. Assay-specific cutoff points for basal or corticotropin (ACTH)-stimulated values must be used [
         <a href="#rid45">
          45,46
         </a>
         ]. (See
         <a class="local">
          'Basal salivary cortisol'
         </a>
         below and
         <a class="local">
          'ACTH-stimulated salivary cortisol'
         </a>
         below.)
        </p>
        <p>
         For women taking oral contraceptives, another option is to discontinue oral contraceptives for six to eight weeks (if able) and perform an
         <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">
          ACTH stimulation test
         </a>
         . (See
         <a class="local">
          'Standard high-dose ACTH stimulation test'
         </a>
         above.)
        </p>
        <p>
         The influence of estrogens on serum total cortisol measurement is illustrated by the following findings [
         <a href="#rid8">
          8,43,46,47
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In women taking oral contraceptives, the serum total cortisol is approximately 1.5 times higher than women not taking oral contraceptives [
         <a href="#rid47">
          47
         </a>
         ]. In one study evaluating the normal response to ACTH in 100 healthy adults (50 men and 50 women) and 13 women taking oral contraceptives, 30-minute total cortisol values were two-fold higher and free cortisol values were lower in the oral contraceptive group compared with controls [
         <a href="#rid43">
          43
         </a>
         ]. A second study of healthy women reported a 1.7 to 2.2- and a 1.3 to 1.6-fold elevation in basal and stimulated total cortisol levels, respectively, in women treated with oral contraceptives compared with those who were not [
         <a href="#rid8">
          8
         </a>
         ] and suggested that women stop oral contraceptive agents before undergoing ACTH stimulation testing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In contrast, transdermal estrogen has less of an influence on CBG and does not appear to increase serum total cortisol [
         <a href="#rid47">
          47
         </a>
         ]. Therefore, it may be unnecessary to discontinue transdermal estrogen prior to evaluation with a morning serum cortisol or
         <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">
          ACTH stimulation test
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         During pregnancy, there is a progressive rise in total cortisol, free cortisol, and CBG. During the third trimester, morning serum total cortisol concentrations may be 50 mcg/dL (1400 nmol/L) or higher. The impact of high CBG levels on cortisol assessment during pregnancy is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/139.html" rel="external">
          "Diagnosis and management of Cushing syndrome during pregnancy", section on 'HPA changes in normal pregnancy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1220099791">
         <span class="h3">
          Low CBG
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serum cortisol in patients with suspected low corticosteroid-binding globulin (CBG) due to nephrotic syndrome, sepsis, or cirrhosis should be interpreted with caution. In the appropriate clinical setting, a morning cortisol above the assay-specific threshold to
         <em>
         </em>
         exclude adrenal insufficiency can exclude adrenal insufficiency.
        </p>
        <p>
         Patients with cirrhosis or nephrotic syndrome who have low CBG values may have "subnormal" morning cortisol [
         <a href="#rid48">
          48
         </a>
         ] and cortisol response to ACTH [
         <a href="#rid41">
          41
         </a>
         ] in the absence of adrenal insufficiency [
         <a href="#rid43">
          43
         </a>
         ]. In this setting, we prefer using salivary cortisol levels to assess for adrenal insufficiency. Assay-specific cutoff points for basal or ACTH-stimulated values must be used [
         <a href="#rid41">
          41
         </a>
         ]. (See
         <a class="local">
          'Basal salivary cortisol'
         </a>
         below and
         <a class="local">
          'ACTH-stimulated salivary cortisol'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2870026451">
         <span class="h3">
          Tests not affected by abnormal CBG
         </span>
        </p>
        <p class="headingAnchor" id="H1568229431">
         <span class="h4">
          Basal salivary cortisol
         </span>
         <span class="headingEndMark">
          —
         </span>
         Measurements of salivary cortisol may be useful in patients with abnormalities of corticosteroid-binding globulin (CBG) because salivary cortisol levels more accurately reflect serum
         <strong>
          free cortisol
         </strong>
         concentrations than do measurements of serum total cortisol. (See
         <a class="local">
          'Abnormal CBG'
         </a>
         above.)
        </p>
        <p>
         Saliva is obtained after rinsing the mouth but before brushing the teeth. A cotton pledget is placed between the gum and cheek or under the tongue until it is saturated with saliva and feels "slimy." Patients should be cautioned not to use lip products that prevent chapping or are colored (gloss, lipstick), as some of these contain
         <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">
          hydrocortisone
         </a>
         and will contaminate the specimen. They should also not remove the pledget with their fingers if they use any type of lotion, which may also contain hydrocortisone. The saturated cotton pledget is placed in the container by protruding it from the mouth, rather than with the fingers. The container can be stored at room temperature for many days or frozen for extended periods.
        </p>
        <p>
         Morning salivary cortisol concentrations are decreased in adrenal insufficiency. Each salivary cortisol assay has a different reference range. The clinician must be familiar with the normative values for the assay being used. In one study using liquid chromatography-tandem mass spectrometry (LC-MS/MS), the normal reference range for salivary cortisol was 0.06 to 1.25 mcg/dL (1.6 to 34.4 nmol/L) [
         <a href="#rid49">
          49
         </a>
         ]. A morning value &lt;0.04 mcg/dL (&lt;1 nmol/L) was diagnostic of adrenal insufficiency, and a value &gt;0.21 mcg/dL (&gt;5.9 nmol/L) excluded it.
        </p>
        <p class="headingAnchor" id="H1963381911">
         <span class="h4">
          ACTH-stimulated salivary cortisol
         </span>
         <span class="headingEndMark">
          —
         </span>
         Salivary cortisol can also be measured during this test and is particularly useful if venous access is problematic or if plasma proteins and presumably CBG levels are abnormal [
         <a href="#rid2">
          2,45
         </a>
         ]. However, there is less experience with it than with serum cortisol [
         <a href="#rid50">
          50,51
         </a>
         ], and many laboratories do not have firmly established corticotropin (ACTH)-stimulated salivary cortisol cutoffs. (See
         <a class="medical medical_review" href="/z/d/html/161.html" rel="external">
          "Measurement of cortisol in serum and saliva"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study measuring salivary cortisol by immunoassay, a conservative cutoff to exclude adrenal insufficiency was &gt;0.9 mcg/dL (&gt;26 nmol/L) one hour after injection of ACTH [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study using LC-MS/MS, the ACTH-stimulated salivary cortisol threshold to exclude adrenal insufficiency was a peak value &gt;0.6 mcg/dL (&gt;17.2 nmol/L) [
         <a href="#rid49">
          49
         </a>
         ]. The thresholds to establish adrenal insufficiency were &lt;0.1 and &lt;0.3 mcg/dL (&lt;3.2 and &lt;9.5 nmol/L) at 30 and 60 minutes, respectively.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Recent ACTH deficiency
         </span>
        </p>
        <p class="headingAnchor" id="H994995948">
         <span class="h3">
          After pituitary surgery or trauma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recent corticotropin (ACTH) deficiency, as may occur soon after pituitary surgery, pituitary apoplexy, or brain or pituitary stalk trauma, may result in a falsely reassuring
         <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">
          ACTH stimulation test
         </a>
         [
         <a href="#rid53">
          53
         </a>
         ]. During the weeks after cessation of ACTH secretion, the zona fasciculata and reticularis of the adrenals undergo functional and anatomical atrophy. During this interval, the adrenals may respond normally to pharmacologic doses of ACTH. However, the pituitary gland is unable to release ACTH in response to stress. Therefore, patients with possible recent ACTH deficiency, even if they have a normal response to ACTH, should be given stress doses of glucocorticoids and
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         during major stress or surgery until repeat ACTH stimulation testing four to six weeks after suspected onset of ACTH deficiency. (See
         <a class="medical medical_review" href="/z/d/html/155.html" rel="external">
          "Treatment of adrenal insufficiency in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6639.html" rel="external">
          "Diagnostic testing for hypopituitarism", section on 'Corticotropin'
         </a>
         .)
        </p>
        <p>
         After pituitary surgery, some experts routinely treat with glucocorticoid replacement until normal adrenal function is demonstrated four to six weeks after surgery. However, others measure serum cortisol on the third postoperative day, 24 hours after the previous dose of glucocorticoids, and only administer replacement glucocorticoids if the value is low (less than 5 mcg/dL [138 nmol/L]) or borderline (5 to 15 mcg/dL [138 to 469 nmol/L]). ACTH testing is performed four to six weeks after onset of adrenal insufficiency to determine if replacement glucocorticoids must be continued. (See
         <a class="medical medical_review" href="/z/d/html/86683.html" rel="external">
          "Transsphenoidal surgery for pituitary adenomas and other sellar masses", section on 'Perioperative management'
         </a>
         .)
        </p>
        <p>
         In rare patients for whom a confirmed diagnosis of adrenal insufficiency cannot be delayed, the insulin-induced hypoglycemia test may be performed to establish the diagnosis. This test is now rarely performed in clinical practice. (See
         <a class="medical medical_review" href="/z/d/html/164.html" rel="external">
          "Insulin-induced hypoglycemia test protocol", section on 'Recent pituitary surgery'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2985418191">
         <span class="h3">
          Partial ACTH deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Corticotropin (ACTH) deficiency occurring after pituitary surgery, hypothalamic-pituitary radiotherapy, trauma, or opioid use may be partial. Partial ACTH deficiency has also been reported after discontinuation of glucocorticoids, including inhaled preparations [
         <a href="#rid54">
          54
         </a>
         ]. Partial ACTH deficiency usually causes symptoms during times of physical stress (eg, febrile illness) when corticotropin-releasing hormone (CRH) and/or ACTH secretion do not increase in response to the stress. However, basal ACTH production may be adequate to prevent adrenal gland atrophy and, therefore, ACTH-stimulated cortisol levels may be normal. (See
         <a class="medical medical_review" href="/z/d/html/6639.html" rel="external">
          "Diagnostic testing for hypopituitarism", section on 'Evaluate for ACTH deficiency'
         </a>
         .)
        </p>
        <p>
         A diagnosis of partial adrenal insufficiency is usually made on clinical grounds alone, typically in patients with a history of pituitary surgery or radiotherapy, who develop signs and symptoms of adrenal insufficiency exclusively during physiologic stress. However, if clinical evaluation is equivocal, the
         <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">
          metyrapone
         </a>
         test can be used to verify the diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/6639.html" rel="external">
          "Diagnostic testing for hypopituitarism", section on 'Evaluate for ACTH deficiency'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/162.html" rel="external">
          "Metyrapone stimulation tests", section on 'Overnight, single-dose metyrapone test'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2623640231">
         <span class="h3">
          Opioid-induced adrenal insufficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Long-term opioid use for the treatment of chronic pain may cause chronic central adrenal insufficiency due to opioid suppression of the HPA axis [
         <a href="#rid55">
          55,56
         </a>
         ]. Opioid-induced adrenal insufficiency should be suspected in people chronically taking opioids who have fatigue, postural hypotension, nausea, weight loss, and hypogonadism [
         <a href="#rid57">
          57
         </a>
         ]. Opioid-induced central hypogonadism is more common than central adrenal insufficiency [
         <a href="#rid56">
          56
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7460.html" rel="external">
          "Causes of secondary hypogonadism in males", section on 'Opioids'
         </a>
         .)
        </p>
        <p>
         The initial testing is the same as for any adrenal insufficiency. Opioid-induced adrenal insufficiency may be difficult to diagnose, particularly if the hypothalamic-pituitary suppression is recent as the
         <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">
          ACTH stimulation test
         </a>
         may show normal results. In this setting, other testing (eg, insulin-induced hypoglycemia test) or a trial of glucocorticoid replacement is warranted. (See
         <a class="local">
          'Diagnostic testing'
         </a>
         above and
         <a class="local">
          'Standard high-dose ACTH stimulation test'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/164.html" rel="external">
          "Insulin-induced hypoglycemia test protocol"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Critical illness
         </span>
         <span class="headingEndMark">
          —
         </span>
         Critically ill patients have reduced metabolic clearance of cortisol, leading to variable serum cortisol and ACTH concentrations [
         <a href="#rid58">
          58,59
         </a>
         ]. There is little consensus about the definition of a "normal" or "appropriate" cortisol level during critical illness. In addition, critically ill patients often have abnormal binding globulins, and laboratory assays of cortisol concentration and cortisol response to ACTH stimulation are generally unreliable. Thus, most clinicians do
         <strong>
          not
         </strong>
         rely on laboratory testing to select glucocorticoid replacement therapy in patients with septic shock. This topic is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1654.html" rel="external">
          "Glucocorticoid therapy in septic shock in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H550126769">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112295.html" rel="external">
          "Society guideline links: Adrenal insufficiency"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10271581">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Whom to test
         </strong>
         – Diagnostic testing should be performed in patients with signs and symptoms of adrenal insufficiency  (
         <a class="graphic graphic_table graphicRef78490" href="/z/d/graphic/78490.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef57534" href="/z/d/graphic/57534.html" rel="external">
          table 2
         </a>
         ). The symptoms of adrenal insufficiency may be subtle, and the diagnosis of adrenal insufficiency depends upon a critical level of clinical suspicion. (See
         <a class="local">
          'Whom to test'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/159.html" rel="external">
          "Clinical manifestations of adrenal insufficiency in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Basal serum cortisol testing
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Suspected adrenal crisis
         </strong>
         – For patients with suspected adrenal crisis, we obtain plasma corticotropin (ACTH) and serum cortisol levels (any time of day) and immediately begin therapy with intravenous (IV)
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         and glucocorticoids. The treatment of patients who present in possible adrenal crisis should not be delayed while awaiting the results of diagnostic testing. (See
         <a class="local">
          'Suspected adrenal crisis'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/155.html" rel="external">
          "Treatment of adrenal insufficiency in adults", section on 'Adrenal crisis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Cortisol &lt;18 mcg/dL
         </strong>
         – In hypotensive patients considered to be in adrenal crisis, a basal serum cortisol level &lt;18 mcg/dL (&lt;500 nmol/L) suggests the diagnosis of adrenal insufficiency. To confirm the diagnosis of adrenal insufficiency, ACTH stimulation testing should be performed at a later date. If supraphysiologic doses of glucocorticoids (40 to 200 mg of
         <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">
          hydrocortisone
         </a>
         daily) have not been given for more than a few days, an
         <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">
          ACTH stimulation test
         </a>
         can be performed after initiation of glucocorticoid treatment. Withhold glucocorticoids on the morning of the test, and resume after the test is completed while awaiting results.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Cortisol ≥18 mcg/dL
         </strong>
         – In the absence of corticosteroid-binding globulin (CBG) excess, a basal serum cortisol level ≥18 mcg/dL (≥500 nmol/L) makes adrenal insufficiency unlikely.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Suspected chronic adrenal insufficiency
         </strong>
         – For patients with suspected chronic adrenal insufficiency, we measure a serum cortisol level within three hours after wakening (eg, 6 to 9 AM)  (
         <a class="graphic graphic_algorithm graphicRef139990" href="/z/d/graphic/139990.html" rel="external">
          algorithm 1
         </a>
         ). When the clinical suspicion for chronic adrenal insufficiency is high, we obtain both serum cortisol and plasma ACTH levels simultaneously. Once a diagnosis of adrenal insufficiency is established, the ACTH level is used to distinguish between primary and central adrenal insufficiency  (
         <a class="graphic graphic_algorithm graphicRef141555" href="/z/d/graphic/141555.html" rel="external">
          algorithm 2
         </a>
         ). (See
         <a class="local">
          'Suspected chronic adrenal insufficiency'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/154.html" rel="external">
          "Determining the etiology of adrenal insufficiency in adults", section on 'ACTH interpretation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Clinical judgement is used in conjunction with the cortisol results to determine whether ACTH stimulation testing should be performed. The interpretation of the serum cortisol result depends on the assay used to measure it. (See
         <a class="local">
          'Influence of cortisol assay technique'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Cortisol ≤3 mcg/dL
         </strong>
         – A low early morning serum cortisol concentration (≤3 mcg/dL [80 nmol/L]) in the absence of CBG deficiency is consistent with adrenal insufficiency. Typically, ACTH stimulation testing is not needed to confirm the diagnosis in these settings, unless there is discordance between symptoms and the cortisol levels.
         <span class="utd-adt-cnt utd-adt-labi">
          (Related Lab Interpretation Monograph(s):
          <a class="narrative narrative_labi" href="/contents/low-cortisol-in-adults?topicRef=157&amp;source=see_link">
           "Low cortisol in adults"
          </a>
          .)
         </span>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Cortisol &gt;3 mcg/dL but &lt;18 mcg/dL
         </strong>
         – If the morning serum cortisol concentration is &gt;3 mcg/dL (&gt;80 nmol/L) but &lt;18 mcg/dL (&lt;500 nmol/L), perform a standard
         <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">
          ACTH stimulation test
         </a>
         . With less cross-reactive cortisol assays, the upper threshold is
         <strong>
          13 to 14 mcg/dL
         </strong>
         (360 to 390 nmol/L) instead of 18 mcg/dL (ie, perform ACTH stimulation test if cortisol is &gt;3 mcg/dL but &lt;13 to 14 mcg/dL). (See
         <a class="local">
          'ACTH stimulation tests'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Cortisol ≥18 mcg/dL
         </strong>
         – An early morning serum cortisol concentration ≥18 mcg/dL (≥500 nmol/L) in the absence of CBG excess excludes primary adrenal insufficiency and most patients with central adrenal insufficiency using many immunoassays. When cortisol is measured using less cross-reactive assays, the morning cortisol threshold to exclude adrenal insufficiency is approximately 25 to 30 percent lower (eg,
         <strong>
          13 to 14
         </strong>
         <strong>
          mcg/dL
         </strong>
         instead of 18 mcg/dL [360 to 390 nmol/L instead of 500 nmol/L]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role of DHEAS measurements
         </strong>
         – We typically measure dehydroepiandrosterone sulfate (DHEAS) when initial biochemical testing with cortisol and ACTH is indeterminate  (
         <a class="graphic graphic_algorithm graphicRef139990" href="/z/d/graphic/139990.html" rel="external">
          algorithm 1
         </a>
         ). However, some UpToDate contributors measure DHEAS in all patients with suspected adrenal insufficiency.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A normal DHEAS (using an age- and sex-specific reference range) makes adrenal insufficiency unlikely. DHEAS levels are low in people with primary or central adrenal insufficiency. Although a low serum DHEAS may raise the clinical suspicion of adrenal insufficiency or support the diagnosis, it is not used as a single test to diagnose adrenal insufficiency. Patients with indeterminate cortisol levels and low (or indeterminate) serum DHEAS should undergo ACTH stimulation testing. (See
         <a class="local">
          'DHEAS'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ACTH stimulation tests
         </strong>
         – A standard high-dose (250 mcg)
         <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">
          ACTH stimulation test
         </a>
         should be performed to establish the diagnosis of adrenal insufficiency in patients with equivocal serum cortisol values in whom hypoadrenalism is suspected. (See
         <a class="local">
          'ACTH stimulation tests'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Interpretation of the
         <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">
          ACTH stimulation test
         </a>
         is based on
         <strong>
          the peak
         </strong>
         serum cortisol value, which typically occurs 60 minutes after administration (but may occur at 30 minutes). The ACTH-stimulated cortisol thresholds to exclude adrenal insufficiency vary with the assay used to measure cortisol  (
         <a class="graphic graphic_table graphicRef134375" href="/z/d/graphic/134375.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Interpretation of results'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Our approach to interpreting the
         <strong>
          peak
         </strong>
         serum cortisol value after ACTH administration is as follows  (
         <a class="graphic graphic_algorithm graphicRef139990" href="/z/d/graphic/139990.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          &lt;14 mcg/dL (390 nmol/L)
         </strong>
         – Adrenal insufficiency likely.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          ≥14 to &lt;18 mcg/dL (390 to 500 nmol/L)
         </strong>
         – The interpretation of the cortisol result depends on the type of assay that is used to measure it  (
         <a class="graphic graphic_table graphicRef134375" href="/z/d/graphic/134375.html" rel="external">
          table 3
         </a>
         ) and the clinical likelihood of adrenal insufficiency in an individual patient. If the assay type is unknown or diagnosis is uncertain, a DHEAS level may be useful. A normal DHEAS (using an age- and sex-specific reference range) makes adrenal insufficiency unlikely. (See
         <a class="local">
          'DHEAS'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          ≥18 mcg/dL (500 nmol/L)
         </strong>
         – Adrenal insufficiency generally excluded regardless of assay used to measure cortisol.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Exceptions include measurements obtained within four to six weeks of interventions (such as pituitary surgery or radiation) that may damage the hypothalamus or pituitary, or measurements obtained in patients with abnormal CBG levels. (See
         <a class="local">
          'Interpretation of results'
         </a>
         above and
         <a class="local">
          'Recent ACTH deficiency'
         </a>
         above and
         <a class="local">
          'Abnormal CBG'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Abnormal CBG level
         </strong>
         – High CBG levels in women using oral contraceptives or low CBG levels in patients with nephrotic syndrome may confound interpretation of serum cortisol levels (basal or during ACTH test). In patients with CBG excess, only a frankly subnormal basal value (≤3 mcg/dL [83 nmol/L]) is useful to make the diagnosis of adrenal insufficiency. Basal values &gt;3 mcg/dL neither confirm nor exclude a diagnosis of adrenal insufficiency. In patients with suspected low CBG due to nephrotic syndrome, sepsis, or cirrhosis, a morning cortisol above the assay-specific threshold to
         <em>
         </em>
         exclude adrenal insufficiency can exclude adrenal insufficiency. However, "subnormal" morning cortisol and cortisol response to ACTH may occur in the absence of adrenal insufficiency. The use of salivary cortisol or serum free cortisol can be helpful when CBG is abnormal. For women taking oral contraceptives, another option is to discontinue oral contraceptives for six to eight weeks (if able) and perform an
         <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">
          ACTH stimulation test
         </a>
         . (See
         <a class="local">
          'Abnormal CBG'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1912648653">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kalaria T, Buch H, Agarwal M, et al. Morning serum cortisol is superior to salivary cortisone and cortisol in predicting normal adrenal function in suspected adrenal insufficiency. Clin Endocrinol (Oxf) 2022; 96:916.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raff H, Brock S, Findling JW. Cosyntropin-stimulated salivary cortisol in hospitalized patients with hypoproteinemia. Endocrine 2008; 34:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sbardella E, Isidori AM, Woods CP, et al. Baseline morning cortisol level as a predictor of pituitary-adrenal reserve: a comparison across three assays. Clin Endocrinol (Oxf) 2017; 86:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manosroi W, Phimphilai M, Khorana J, Atthakomol P. Diagnostic performance of basal cortisol level at 0900-1300h in adrenal insufficiency. PLoS One 2019; 14:e0225255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ravindran R, Carter JL, Kumar A, et al. Pre-test Cortisol Levels in Predicting Short Synacthen Test Outcome: A Retrospective Analysis. Clin Med Insights Endocrinol Diabetes 2022; 15:11795514221093316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar R, Carr P, Wassif W. Diagnostic performance of morning serum cortisol as an alternative to short synacthen test for the assessment of adrenal reserve; a retrospective study. Postgrad Med J 2022; 98:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Farhan N, Pickett A, Ducroq D, et al. Method-specific serum cortisol responses to the adrenocorticotrophin test: comparison of gas chromatography-mass spectrometry and five automated immunoassays. Clin Endocrinol (Oxf) 2013; 78:673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woods CP, Argese N, Chapman M, et al. Adrenal suppression in patients taking inhaled glucocorticoids is highly prevalent and management can be guided by morning cortisol. Eur J Endocrinol 2015; 173:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michaelidou M, Yadegarfar G, Morris L, et al. Recalibration of thinking about adrenocortical function assessment: how the 'random' cortisol relates to the short synacthen test results. Cardiovasc Endocrinol Metab 2021; 10:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathara Diddhenipothage SAD, Beck KJ, Loo H, et al. "A morning cortisol is the most effective clinical predictor of short synacthen test outcome": A tertiary care centre experience. Clin Endocrinol (Oxf) 2023; 99:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fragoso Perozo AFD, Fontes R, Lopes FP, et al. Morning serum cortisol role in the adrenal insufficiency diagnosis with modern cortisol assays. J Endocrinol Invest 2023; 46:2115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt IL, Lahner H, Mann K, Petersenn S. Diagnosis of adrenal insufficiency: Evaluation of the corticotropin-releasing hormone test and Basal serum cortisol in comparison to the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease. J Clin Endocrinol Metab 2003; 88:4193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deutschbein T, Unger N, Mann K, Petersenn S. Diagnosis of secondary adrenal insufficiency: unstimulated early morning cortisol in saliva and serum in comparison with the insulin tolerance test. Horm Metab Res 2009; 41:834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hägg E, Asplund K, Lithner F. Value of basal plasma cortisol assays in the assessment of pituitary-adrenal insufficiency. Clin Endocrinol (Oxf) 1987; 26:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Javorsky BR, Raff H, Carroll TB, et al. New Cutoffs for the Biochemical Diagnosis of Adrenal Insufficiency after ACTH Stimulation using Specific Cortisol Assays. J Endocr Soc 2021; 5:bvab022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gasco V, Bima C, Geranzani A, et al. Morning Serum Cortisol Level Predicts Central Adrenal Insufficiency Diagnosed by Insulin Tolerance Test. Neuroendocrinology 2021; 111:1238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramadoss V, Lazarus K, Prevost AT, et al. Improving the Interpretation of Afternoon Cortisol Levels and SSTs to Prevent Misdiagnosis of Adrenal Insufficiency. J Endocr Soc 2021; 5:bvab147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colling C, Nachtigall L, Biller BMK, Miller KK. The biochemical diagnosis of adrenal insufficiency with modern cortisol assays: Reappraisal in the setting of opioid exposure and hospitalization. Clin Endocrinol (Oxf) 2022; 96:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Roux CW, Meeran K, Alaghband-Zadeh J. Is a 0900-h serum cortisol useful prior to a short synacthen test in outpatient assessment? Ann Clin Biochem 2002; 39:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Aridi R, Abdelmannan D, Arafah BM. Biochemical diagnosis of adrenal insufficiency: the added value of dehydroepiandrosterone sulfate measurements. Endocr Pract 2011; 17:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tordjman K, Jaffe A, Greenman Y, Stern N. Comments on the comparison of low and high dose corticotropin stimulation tests in patients with pituitary disease. J Clin Endocrinol Metab 1998; 83:4530; author reply 4532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raff H, Findling JW, Wong J. Short loop adrenocorticotropin (ACTH) feedback after ACTH-(1-24) injection in man is an artifact of the immunoradiometric assay. J Clin Endocrinol Metab 1989; 69:678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hawkins JB Jr, Burch WM. Rapid tests of adrenocortical function. Intravenous versus intramuscular administration of synthetic ACTH. N C Med J 1989; 50:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aimaretti G, Baffoni C, Di Vito L, et al. Hypopituitaric patients with corticotropin insufficiency show marked impairment of the cortisol response to ACTH (1-24) independently of the duration of the disease. J Endocrinol Invest 2003; 26:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kehlet H, Binder C. Value of an ACTH test in assessing hypothalamic-pituitary-adrenocortical function in glucocorticoid-treated patients. Br Med J 1973; 2:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           May ME, Carey RM. Rapid adrenocorticotropic hormone test in practice. Retrospective review. Am J Med 1985; 79:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Speckart PF, Nicoloff JT, Bethune JE. Screening for adrenocortical insufficiency with cosyntropin (synthetic ACTH). Arch Intern Med 1971; 128:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Husni H, Abusamaan MS, Dinparastisaleh R, et al. Cortisol values during the standard-dose cosyntropin stimulation test: Personal experience with Elecsys cortisol II assay. Front Endocrinol (Lausanne) 2022; 13:978238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahzari M, AlSohaim A, Al Mulla A, et al. Variations in cortisol response in patients with known and suspected adrenal insufficiency. Medicine (Baltimore) 2022; 101:e32557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hawley JM, Owen LJ, Lockhart SJ, et al. Serum Cortisol: An Up-To-Date Assessment of Routine Assay Performance. Clin Chem 2016; 62:1220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zha L, Li J, Krishnan SM, et al. New Diagnostic Cutoffs for Adrenal Insufficiency After Cosyntropin Stimulation Using Abbott Architect Cortisol Immunoassay. Endocr Pract 2022; 28:684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wade M, Baid S, Calis K, et al. Technical details influence the diagnostic accuracy of the 1 microg ACTH stimulation test. Eur J Endocrinol 2010; 162:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ospina NS, Al Nofal A, Bancos I, et al. ACTH Stimulation Tests for the Diagnosis of Adrenal Insufficiency: Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 2016; 101:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dorin RI, Qualls CR, Crapo LM. Diagnosis of adrenal insufficiency. Ann Intern Med 2003; 139:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nieman LK. Dynamic evaluation of adrenal hypofunction. J Endocrinol Invest 2003; 26:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laureti S, Candeloro P, Aglietti MC, et al. Dehydroepiandrosterone, 17alpha-hydroxyprogesterone and aldosterone responses to the low-dose (1 micro g) ACTH test in subjects with preclinical adrenal autoimmunity. Clin Endocrinol (Oxf) 2002; 57:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Honour JW, Bridges NA, Conway-Phillips E, Hindmarsh PC. Plasma aldosterone response to the low-dose adrenocorticotrophin (ACTH 1-24) stimulation test. Clin Endocrinol (Oxf) 2008; 68:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Contreras LN, Arregger AL, Persi GG, et al. A new less-invasive and more informative low-dose ACTH test: salivary steroids in response to intramuscular corticotrophin. Clin Endocrinol (Oxf) 2004; 61:675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peechakara S, Bena J, Clarke NJ, et al. Total and free cortisol levels during 1 μg, 25 μg, and 250 μg cosyntropin stimulation tests compared to insulin tolerance test: results of a randomized, prospective, pilot study. Endocrine 2017; 57:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galbois A, Rudler M, Massard J, et al. Assessment of adrenal function in cirrhotic patients: salivary cortisol should be preferred. J Hepatol 2010; 52:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan T, Chang L, Woodward A, et al. Characterising adrenal function using directly measured plasma free cortisol in stable severe liver disease. J Hepatol 2010; 53:841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klose M, Lange M, Rasmussen AK, et al. Factors influencing the adrenocorticotropin test: role of contemporary cortisol assays, body composition, and oral contraceptive agents. J Clin Endocrinol Metab 2007; 92:1326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dichtel LE, Schorr M, Loures de Assis C, et al. Plasma Free Cortisol in States of Normal and Altered Binding Globulins: Implications for Adrenal Insufficiency Diagnosis. J Clin Endocrinol Metab 2019; 104:4827.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cornes MP, Ashby HL, Khalid Y, et al. Salivary cortisol and cortisone responses to tetracosactrin (synacthen). Ann Clin Biochem 2015; 52:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ambroziak U, Kondracka A, Bartoszewicz Z, et al. The morning and late-night salivary cortisol ranges for healthy women may be used in pregnancy. Clin Endocrinol (Oxf) 2015; 83:774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qureshi AC, Bahri A, Breen LA, et al. The influence of the route of oestrogen administration on serum levels of cortisol-binding globulin and total cortisol. Clin Endocrinol (Oxf) 2007; 66:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westerdijk RH, Wolffenbuttel BH, Kema IP, Wouters RS. [Hypocortisolism associated with nephrotic syndrome]. Ned Tijdschr Geneeskd 2017; 160:D669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langelaan MLP, Kisters JMH, Oosterwerff MM, Boer AK. Salivary cortisol in the diagnosis of adrenal insufficiency: cost efficient and patient friendly. Endocr Connect 2018; 7:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim YJ, Kim JH, Hong AR, et al. Stimulated Salivary Cortisol as a Noninvasive Diagnostic Tool for Adrenal Insufficiency. Endocrinol Metab (Seoul) 2020; 35:628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan SYT, Tan HC, Zhu L, et al. Expanding the use of salivary cortisol as a non-invasive outpatient test in the dynamic evaluation of suspected adrenal insufficiency. Endocr Connect 2023; 12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nolan BJ, Sorbello J, Brown N, et al. Characterization of the serum and salivary cortisol response to the intravenous 250 µg ACTH1-24 stimulation test. Endocrine 2018; 59:520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borst GC, Michenfelder HJ, O'Brian JT. Discordant cortisol response to exogenous ACTH and insulin-induced hypoglycemia in patients with pituitary disease. N Engl J Med 1982; 306:1462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prete A, Bancos I. Glucocorticoid induced adrenal insufficiency. BMJ 2021; 374:n1380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donegan D, Bancos I. Opioid-Induced Adrenal Insufficiency. Mayo Clin Proc 2018; 93:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gadelha MR, Karavitaki N, Fudin J, et al. Opioids and pituitary function: expert opinion. Pituitary 2022; 25:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donegan D. Opioid induced adrenal insufficiency: what is new? Curr Opin Endocrinol Diabetes Obes 2019; 26:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raff H, Sharma ST, Nieman LK. Physiological basis for the etiology, diagnosis, and treatment of adrenal disorders: Cushing's syndrome, adrenal insufficiency, and congenital adrenal hyperplasia. Compr Physiol 2014; 4:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer EJ, Nenke MA, Davies ML, et al. Corticosteroid-Binding Globulin Deficiency Independently Predicts Mortality in Septic Shock. J Clin Endocrinol Metab 2022; 107:1636.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 157 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33290598" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Morning serum cortisol is superior to salivary cortisone and cortisol in predicting normal adrenal function in suspected adrenal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18946745" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Cosyntropin-stimulated salivary cortisol in hospitalized patients with hypoproteinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26760044" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27616279" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Baseline morning cortisol level as a predictor of pituitary-adrenal reserve: a comparison across three assays.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31738804" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Diagnostic performance of basal cortisol level at 0900-1300h in adrenal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35558546" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Pre-test Cortisol Levels in Predicting Short Synacthen Test Outcome: A Retrospective Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33122342" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Diagnostic performance of morning serum cortisol as an alternative to short synacthen test for the assessment of adrenal reserve; a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22994849" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Method-specific serum cortisol responses to the adrenocorticotrophin test: comparison of gas chromatography-mass spectrometry and five automated immunoassays.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26294794" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Adrenal suppression in patients taking inhaled glucocorticoids is highly prevalent and management can be guided by morning cortisol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34113799" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Recalibration of thinking about adrenocortical function assessment: how the 'random' cortisol relates to the short synacthen test results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37288515" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : "A morning cortisol is the most effective clinical predictor of short synacthen test outcome": A tertiary care centre experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36966469" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Morning serum cortisol role in the adrenal insufficiency diagnosis with modern cortisol assays.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12970286" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Diagnosis of adrenal insufficiency: Evaluation of the corticotropin-releasing hormone test and Basal serum cortisol in comparison to the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19585406" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Diagnosis of secondary adrenal insufficiency: unstimulated early morning cortisol in saliva and serum in comparison with the insulin tolerance test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3311477" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Value of basal plasma cortisol assays in the assessment of pituitary-adrenal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33768189" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : New Cutoffs for the Biochemical Diagnosis of Adrenal Insufficiency after ACTH Stimulation using Specific Cortisol Assays.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33406519" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Morning Serum Cortisol Level Predicts Central Adrenal Insufficiency Diagnosed by Insulin Tolerance Test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34611573" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Improving the Interpretation of Afternoon Cortisol Levels and SSTs to Prevent Misdiagnosis of Adrenal Insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34498295" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The biochemical diagnosis of adrenal insufficiency with modern cortisol assays: Reappraisal in the setting of opioid exposure and hospitalization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11930947" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Is a 0900-h serum cortisol useful prior to a short synacthen test in outpatient assessment?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21134877" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Biochemical diagnosis of adrenal insufficiency: the added value of dehydroepiandrosterone sulfate measurements.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9851806" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Comments on the comparison of low and high dose corticotropin stimulation tests in patients with pituitary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2547830" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Short loop adrenocorticotropin (ACTH) feedback after ACTH-(1-24) injection in man is an artifact of the immunoradiometric assay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2662018" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Rapid tests of adrenocortical function. Intravenous versus intramuscular administration of synthetic ACTH.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12602534" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Hypopituitaric patients with corticotropin insufficiency show marked impairment of the cortisol response to ACTH (1-24) independently of the duration of the disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4349334" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Value of an ACTH test in assessing hypothalamic-pituitary-adrenocortical function in glucocorticoid-treated patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3000177" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Rapid adrenocorticotropic hormone test in practice. Retrospective review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4330323" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Screening for adrenocortical insufficiency with cosyntropin (synthetic ACTH).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36060940" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Cortisol values during the standard-dose cosyntropin stimulation test: Personal experience with Elecsys cortisol II assay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36595973" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Variations in cortisol response in patients with known and suspected adrenal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27440512" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Serum Cortisol: An Up-To-Date Assessment of Routine Assay Performance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35487459" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : New Diagnostic Cutoffs for Adrenal Insufficiency After Cosyntropin Stimulation Using Abbott Architect Cortisol Immunoassay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19797501" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Technical details influence the diagnostic accuracy of the 1 microg ACTH stimulation test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26649617" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : ACTH Stimulation Tests for the Diagnosis of Adrenal Insufficiency: Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12899587" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Diagnosis of adrenal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14604069" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Dynamic evaluation of adrenal hypofunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12390344" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Dehydroepiandrosterone, 17alpha-hydroxyprogesterone and aldosterone responses to the low-dose (1 micro g) ACTH test in subjects with preclinical adrenal autoimmunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17868383" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Plasma aldosterone response to the low-dose adrenocorticotrophin (ACTH 1-24) stimulation test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15579180" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : A new less-invasive and more informative low-dose ACTH test: salivary steroids in response to intramuscular corticotrophin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28730418" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Total and free cortisol levels during 1μg, 25μg, and 250μg cosyntropin stimulation tests compared to insulin tolerance test: results of a randomized, prospective, pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20385427" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Assessment of adrenal function in cirrhotic patients: salivary cortisol should be preferred.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20739086" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Characterising adrenal function using directly measured plasma free cortisol in stable severe liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17244781" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Factors influencing the adrenocorticotropin test: role of contemporary cortisol assays, body composition, and oral contraceptive agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31009049" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Plasma Free Cortisol in States of Normal and Altered Binding Globulins: Implications for Adrenal Insufficiency Diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25724424" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Salivary cortisol and cortisone responses to tetracosactrin (synacthen).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26173372" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The morning and late-night salivary cortisol ranges for healthy women may be used in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17492949" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : The influence of the route of oestrogen administration on serum levels of cortisol-binding globulin and total cortisol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28098040" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : [Hypocortisolism associated with nephrotic syndrome].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29531158" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Salivary cortisol in the diagnosis of adrenal insufficiency: cost efficient and patient friendly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32981305" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Stimulated Salivary Cortisol as a Noninvasive Diagnostic Tool for Adrenal Insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36799247" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Expanding the use of salivary cortisol as a non-invasive outpatient test in the dynamic evaluation of suspected adrenal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29299794" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Characterization of the serum and salivary cortisol response to the intravenous 250 µg ACTH1-24 stimulation test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6281642" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Discordant cortisol response to exogenous ACTH and insulin-induced hypoglycemia in patients with pituitary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34253540" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Glucocorticoid induced adrenal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29976376" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Opioid-Induced Adrenal Insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35066756" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Opioids and pituitary function: expert opinion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30870182" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Opioid induced adrenal insufficiency: what is new?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24715566" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Physiological basis for the etiology, diagnosis, and treatment of adrenal disorders: Cushing's syndrome, adrenal insufficiency, and congenital adrenal hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35152290" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Corticosteroid-Binding Globulin Deficiency Independently Predicts Mortality in Septic Shock.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
